Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Change in Antimicrobial Use During COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study

Hana R. Winders, Pamela Bailey, Joseph Kohn, Carmen M. Faulkner-Fennell, Sara Utley, Evan Lantz, Lloyd Sarbacker, Julie Ann Justo, P. Brandon Bookstaver, Sharon Weissman, Hannah Ruegner, Majdi N. Al-Hasan

1. Introduction

Due to the novel nature of the COVID-19 pandemic, little was initially known regarding bacterial co-infection rates with this viral pneumonia. Early in the pandemic, up to three-quarters of hospitalised adults with COVID-19 were prescribed empiric antibacterial agents [1–3]. As the pandemic progressed, evidence emerged that bacterial co-infections ranged from 3.5–8.1% in hospitalised patients with COVID-19 [3–6]. Within the United States, there were notable increases in antimicrobial prescribing rates, including broad-spectrum antimicrobials, with more severe COVID-19 disease presentation [3].

Antimicrobial stewardship programs (ASPs) are critical components of hospital safety and quality teams, as they play an essential role in developing local treatment guidelines and assisting front-
line healthcare providers [7]. ASPs have longstanding roles in optimising selection of empiric antimicrobial therapy and assisting with targeted de-escalation [8]. However, during the initial days of the pandemic, many ASP resources were repurposed to support the needs of healthcare systems during the pandemic, limiting their time for dedicated ASP initiatives [9]. This reprioritisation of ASP workflow, the lack of clinical data, and modifications in ASP team dynamics with frontline providers during the pandemic created the potential for amplification of inappropriate antimicrobial prescribing [9].

This multicentre, retrospective, observational cohort study aimed to compare overall and broad-spectrum antimicrobial use during the pandemic (March–June 2020) with the same months of the previous year in hospitals that admitted patients with COVID-19 and those that did not admit patients with COVID-19 in South Carolina.

2. Materials and methods

2.1. Settings

All 22 hospitals in South Carolina that submitted antimicrobial use data to the National Healthcare Safety Network (NHSN) in March–June 2019 and March–June 2020, and gave permission to the South Carolina Department of Health and Environmental Control and the Antimicrobial Stewardship Collaborative of South Carolina to access their antimicrobial use data, were invited to participate in this study.

2.2. Data collection

Overall antimicrobial use for all antibacterial agents, broad-spectrum antibacterial agents predominantly used for hospital-onset infections, broad-spectrum antibacterial agents predominantly used for community-acquired infections, and antibacterial agents predominantly used for resistant Gram-positive infections were collected from the NHSN’s antimicrobial use option.

2.3. Definitions

Broad-spectrum antibacterial agents predominantly used for hospital-onset infections included antipseudomonal penicillins, cephalosporins, carbenpemems, and aminoglycosides. Broad-spectrum agents predominantly used for community-acquired infections included third-generation cephalosporins and fluoroquinolones. Antibacterial agents predominantly used for resistant Gram-positive infections included vancomycin and other agents with activity against methicillin-resistant Staphylococcus aureus (MRSA) [10]. From the NHSN, standardised antimicrobial administration ratios (SAARs), a ratio of reported antimicrobial days over statistically modelled antimicrobial days, were also included to more easily compare AU between hospitals [11].

2.4. Statistical analysis

Antimicrobial use in days of therapy (DOT) per 1000 days-present was evaluated. Matched-pairs mean difference was used to compare antimicrobial use during the pandemic (March–June 2020) and the same time period in the previous year (March–June 2019) in hospitals that did and did not admit patients with COVID-19 in March–June 2020. JMP Pro (version 13.0, SAS Institute Inc., Cary, North Carolina, USA) was used for statistical analysis. The level of significance for statistical testing was defined as two-sided $P < 0.05$.

3. Results

3.1. Characteristics of participating hospitals

Seventeen of the 22 invited hospitals (77%) agreed to participate in the study. Of the 17 included hospitals in the analysis, seven admitted patients with COVID-19 in March–June 2020 and the remaining 10 did not. Hospitals that admitted patients with COVID-19 were relatively larger, more likely to have in-house ASPs (a pharmacist or physician available within that hospital), and had lower baseline SAARs in 2019 than comparators (Table 1).

3.2. Antimicrobial use in hospitals that admitted patients with COVID-19

In the seven hospitals that admitted patients with COVID-19, there was a significant increase in overall antimicrobial use during the pandemic (mean difference (MD) 34.9 DOT/1000 days-present; 95% CI 4.3, 65.6; $P = 0.03$; Figure 1). This corresponded to a 6.6% increase in overall antimicrobial use from March–June 2019 to the same months in 2020. Most of the increase in antimicrobial use in these seven hospitals was observed in broad-spectrum agents predominantly used for hospital-onset infections (16.4% increase from 122.3 in 2019 to 142.5 DOT/1000 days-present in 2020). There was also a 9.5% increase in the use of broad-spectrum Gram-positive agents in these seven hospitals from 66.7 to 73.3 DOT/1000 days-present.

3.3. Antimicrobial use in hospitals that did not admit patients with COVID-19

There were no significant changes in overall antimicrobial use, broad-spectrum agents predominantly used for hospital-onset infections, or broad-spectrum Gram-positive agents in hospitals that did not admit patients with COVID-19. Conversely, there was a significant decline in antimicrobial use of broad-spectrum agents predominantly used for community-acquired infections in these hospitals in March–June 2020 compared with 2019 (Table 1; Figure 1).

4. Discussion

4.1. Antimicrobial use during the pandemic

There was a significant increase in the overall antimicrobial use in the South Carolina hospitals that admitted patients with COVID-19 during the pandemic when compared with the same time period in the previous year. Increases were specifically observed in the use of broad-spectrum agents, particularly anti-pseudomonal beta-lactams and anti-MRSA agents. Interestingly, similar increases in antimicrobial use were not demonstrated in hospitals that did not admit patients with COVID-19. Treating patients with COVID-19 appears to drive overall and broad-spectrum antimicrobial use in hospitals.

The COVID-19 pandemic has imposed unprecedented challenges on ASPs and threatened to erase the gains made in this field over the past few years. A multicentre cohort study of 84 Veterans Administration hospitals in the United States recently reported a decline in antimicrobial use from 2015 through 2019 [12]. However, the increase in antimicrobial use observed in January–May 2020 negated the prior years of antimicrobial stewardship improvements [12]. Reports of increased antimicrobial use early in the COVID-19 pandemic also emerged from single medical centres in the United States and Singapore [13–15]. It is believed that this is the first study to contrast the change in antimicrobial use during the pandemic in hospitals that did and did not admit patients with COVID-19.
Table 1
Hospital characteristics and antimicrobial use in March–June 2019 and 2020 in hospitals that admitted COVID-19 and non-COVID-19 patients.

| Variable                                      | Hospitals that admitted COVID-19 patients (n=7) | Hospitals that did not admit COVID-19 patients (n=10) |
|-----------------------------------------------|-----------------------------------------------|------------------------------------------------------|
| Bed size, n (%)                               |                                               |                                                      |
| < 200                                         | 1 (14)                                        | 9 (90)                                               |
| 200–499                                       | 3 (43)                                        | 1 (10)                                              |
| ≥ 500                                         | 3 (43)                                        | 0 (0)                                                |
| In-house ASP, n (%)                           | 7 (100)                                       | 5 (50)                                               |
| Hospital occupancy                            |                                               |                                                      |
| Mean hospital days present in 2019            | 27 642                                        | 6364                                                 |
| Mean hospital days present in 2020            | 22 657                                        | 5114                                                 |
| Mean SAAR (95% CI); all antimicrobial agents in all adult locations |                                               |                                                      |
| 2019                                          | 0.84 (0.70, 0.98)                             | 1.07 (0.93, 1.22)                                    |
| 2020                                          | 0.92 (0.76, 1.07)                             | 1.08 (0.95, 1.21)                                    |
| Overall AU for all antimicrobials              |                                               |                                                      |
| Mean AU in 2019                               | 530.9                                         | 647.0                                                |
| Mean AU in 2020                               | 565.8                                         | 653.0                                                |
| Broad-spectrum agents used for hospital-onset infections |                                               |                                                      |
| Mean AU in 2019                               | 122.3                                         | 172.1                                                |
| Mean AU in 2020                               | 142.5                                         | 168.9                                                |
| Broad-spectrum agents used for community-acquired infections |                                               |                                                      |
| Mean AU in 2019                               | 110.4                                         | 176.0                                                |
| Mean AU in 2020                               | 119.5                                         | 157.8                                                |
| Agents used for resistant Gram-positive infections |                                               |                                                      |
| Mean AU in 2019                               | 66.7                                          | 90.1                                                 |
| Mean AU in 2020                               | 73.3                                          | 83.0                                                 |

Abbreviations: ASP, antimicrobial stewardship program; SAAR, standardised antimicrobial administration ratio; CI, confidence intervals; AU, antimicrobial use

Antimicrobial use is reported in days of therapy per 1000 days-present

4.2. Potential consequences of increased antimicrobial use

The increase in overall antimicrobial use during the pandemic is concerning. However, the steeper rise in the use of broad-spectrum agents in hospitals that admitted patients with COVID-19 is even more alarming. These results are consistent with a recent large review reporting that > 70% of patients with COVID-19 received antimicrobials, the majority being broad-spectrum antibacterial agents [2,4]. This is despite the low incidence of bacterial co-infection, ranging from 5.9% in all hospitalised patients to 8.1% in critically ill patients, with bacterial superinfections reported as high as 20% [4,16]. The most common organisms identified in superinfections include *Acinetobacter* spp., *Pseudomonas*, and *Escherichia coli*, indicating likely need for broad-spectrum coverage; however, the risks of these agents must be considered [16]. The increasing use of broad-spectrum agents predominantly used for hospital-onset infections in the current study is particularly concerning for antimicrobial stewards, given the high risk of hospital-onset *Clostridioides difficile* infections associated with the heavy use of these broad-spectrum agents [8,17]. Although some aspects of infection prevention, such as hand hygiene, personal protective equipment, and environmental hygiene, are heightened, other
risks for nosocomial spread of infection have lessened monitoring, such as contact isolation, admission screening, and ASP [9]. In New York City, worsening Enterobacterales susceptibility rates during the pandemic were observed compared with data from 2018–2019 [5]. The spread of carbapenem-resistant Gram-negative bacteria and Candida auris was described in acute care hospitals and intensive care units during the peak of the pandemic in Italy and the United States [18–20]; specific lapses in standard infection prevention practices were noted [20].

4.3. Unique antimicrobial stewardship challenges

In addition to increased antimicrobial use in hospitalised patients with COVID-19, other structural changes to ASP during the pandemic likely influenced the study results. Stevens and colleagues discussed the many roles that ASP members may play in COVID-19 response efforts, including assisting with creating treatment guidelines and facilitating the use of medications approved by emergency-use authorisation [7]. In South Carolina, many ASP members had their workloads redirected towards other duties like procuring and facilitating remdesivir usage, as well as developing guidelines for its usage and covering non-ASP-related tasks for pharmacy furloughs. Diversion of ASP resources may also limit the effectiveness of antimicrobials post-prescription audit and feedback interventions. Although all hospitals that admitted patients with COVID-19 in South Carolina had in-house ASP and robust baseline antimicrobial use metrics based on 2019 SAAR data, they were not immune to the great challenges posed by the COVID-19 pandemic. All these factors likely contributed to higher overall and broad-spectrum antimicrobial use during the pandemic in hospitals that admitted patients with COVID-19. It is speculated that less disruption in the daily workflow of ASPs likely resulted in stable overall antimicrobial use during the pandemic in hospitals that did not admit patients with COVID-19, and even a decline in one category, possibly due to ongoing efforts to reduce already high baseline antimicrobial use.

4.4. Strengths and limitations

The multicentre design and accounting for seasonal variation in antimicrobial use by comparing March–June 2020 with the same months in 2019 were major strengths of this study. The study shares common limitations of observational cohorts, including not accounting for unknown or unmeasured confounders. In addition, the study examined quantitative antimicrobial use in hospitals and did not include patient-level data to assess appropriateness, including potential increases in intensive care populations during the COVID-19 pandemic or decreases in ICU due to cancelled elective procedures. There is speculation about sicker populations making up hospital admissions other than COVID-19 patients during the pandemic, affecting antimicrobial use, but this has not yet been quantified. In one study of hospital admissions during the pandemic, largely flat mortality rates implied that total in-hospital deaths decreased on par with decreased in-hospital admissions, so the assumption of sicker patients still seeking medical care may not bear out [21]. It remains undetermined whether the increase in antimicrobial use in hospitals that admitted COVID-19 patients was mostly due to excessive antimicrobial use in patients with COVID-19 or disruption of routine antimicrobial stewardship activities. The proportion of hospital admissions due to COVID-19 early in the pandemic was not available in most hospitals that admitted COVID-19 patients. There was a numerical overall decline in hospital occupancy in all participating hospitals in the study – this was likely due to suspension of elective procedures and other mitigation policies early in the pandemic in South Carolina. The specific impact of these changes on patient demographics were not measured in this study. Finally, the study was confined to a specific geographical area so the results may not be generalisable to other regions.

5. Conclusions

A significant increase in overall and broad-spectrum antimicrobial use was observed in hospitals that admitted patients with COVID-19 in South Carolina. The pandemic continues to stress and test the resilience of healthcare systems and ASPs alike. At a time when resources may be limited, keeping the focus on patient safety and quality teams within hospitals is more important than ever before. Healthcare providers must continue to work together towards judicious antimicrobial use in the face of the developing knowledge regarding COVID-19.

Funding

This study was made possible by funding from the South Carolina Center for Rural and Primary Healthcare in Columbia, South Carolina towards expansion of the Antimicrobial Stewardship Collaboration of South Carolina using TeleECCHO model.

Ethical Approval

The study was approved by the University of South Carolina Institutional Review Board (Columbia, SC, USA).

Declarations of Competing Interests

PB, JK, CMF, SL, EL, LS, SW, and MNA: no conflicts

HRW: bioMérieux, Speaker’s Bureau (nonbranded content); JJ: bioMérieux, Speaker’s Bureau (nonbranded content), Merck, Advisory Board; PBB: bioMérieux, Speaker’s Bureau (nonbranded content), Kedrión Biopharma Advisory Board, research grant.

Acknowledgements

The authors thank all team members of the antimicrobial stewardship programs in the 17 participating hospitals in the study and the Antimicrobial Stewardship Collaborative of South Carolina. HRW and MNA had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the analysis.

References

[1] Clancy CJ, Nguyen MH. Coronavirus disease 2019, superinfections, and antimicrobial development: What can we expect? Clin Inf Dis 2020;ciaa524 [Online ahead of print]. doi:10.1093/cid/ciaa524.
[2] Langford BJ, So M, Raybardhan S, Leung V, Soucy JK, Westwood D, Daneman N, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021 STHR-743X/20/30776-3[Online ahead of print]. doi:10.1016/j.cmi.2020.12.018.
[3] Vaughn VM, Gandhi T, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric antibiotic therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin Inf Dis 2020;ciaa1239 [Online ahead of print]. doi:10.1093/cid/ciaa1239.
[4] Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020;26:1622–9.
[5] Nori P, Cowman K, Chen V, Bartash R, Szymczak W, Madaline T, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021;42:84–8.
[6] Rawson TM, Moore LS, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020;71:2459–68.
[7] Stevens MP, Patel PK, Nori P. Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck. Infect Control Hosp Epidemiol 2020;41:744–5.
[8] Seddon MM, Bookstaver PB, Justo JA, Kohn J, Rac H, Haggard E, et al. Role of early de-escalation of antimicrobial therapy on risk of Clostridioides difficile infection following Enterobacteriaceae bloodstream infections. Clin Infect Dis 2019;69:414–20.

[9] Rawson TM, Moore LS, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother 2020;75:1681–4.

[10] van Santen KL, Edwards JR, Webb AK, Pollack LA, O’Leary E, Neuhauser MM, et al. The standardized antimicrobial administration ratio: a new metric for measuring and comparing antibiotic use. Clin Infect Dis 2018;67(2):179–85.

[11] Al-Hasan MN, Winders HR, Bookstaver PB, Justo JA. Direct measurement of performance: a new era in antimicrobial stewardship. Antibiotics (Basel) 2019;8:127. doi:10.3390/antibiotics8030127.

[12] Dieringer TD, Furukama D, Graber CJ, Stevens VW, Jones MM, Rubin M, et al. Inpatient antibiotic utilization in the Veterans Administration during the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol 2020 [Online ahead of print]. doi:10.1017/ice.2020.1277.

[13] Nestler M, Godbout E, Lee K, Kim J, Noda A, Taylor P, et al. Impact of COVID-19 on pneumonia-focused antibiotic use at an academic medical center. Infect Control Hosp Epidemiol 2020 [Online ahead of print]. doi:10.1017/ice.2020.362.

[14] Liew Y, Lee WHL, Tan L, Kwa ALH, Thien SY, Chong BPZ, et al. Antimicrobial stewardship programme: a vital resource for hospitals during the global outbreak of coronavirus disease 2019 (COVID-19). Int J Antimicrob Agents 2020;56:106145.

[15] Abilena-Alonso G, Padulles A, Rombauts A, Gudiol C, Pujol M, Alvarez-Pouso C, et al. Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern. Infect Control Hosp Epidemiol 2020;41:1371–2.

[16] Musuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS One 2021;16(5):e0253170.

[17] Harris AD, Sbarra AN, Leekha S, Jackson SS, Johnson JK, Pineles L, et al. Electronically available comorbid conditions for risk prediction of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol 2018;39:207–301.

[18] Magnuson I, Mikulska M, Giacobbe DR, Taramasso L, Vena A, Dentone C, et al. Spread of carbapenem-resistant Gram-negatives and Candida auris during the COVID-19 pandemic in critically ill patients: One step back in antimicrobial stewardship? Microorganisms 2021;9:95. doi:10.3390/microorganisms9010095.

[19] Perez S, Innes GK, Walters MS, Mehr J, Arias J, Greeley R, et al. Increase in hospital-acquired carbapenem-resistant Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions - New Jersey, February-July 2020. Morb Mortal Wkly Rep 2020;69:1827–31. doi:10.15585/mmwr.mm6948e1.

[20] Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA, Kuhar D, et al. Candida auris Outbreak in a COVID-19 Specialty Care Unit—Florida. July-August 2020. Morb Mortal Wkly Rep 2021;70:56–2.

[21] Birkmeyer JD, Barnato A, Birkmeyer N, Bessler R, Skinner J. The impact of the COVID-19 pandemic on hospital admission in the United States. Health Affairs 2020;39:2010–17.